Becker Muscular Dystrophy - Pipeline Review, H2 2020

August 2020 | 95 pages | ID: BEE2028C6C4EN
Global Markets Direct

Abstracts

Becker Muscular Dystrophy - Pipeline Review, H2 2020

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Becker Muscular Dystrophy - Pipeline Review, H2 2020, provides an overview of the Becker Muscular Dystrophy (Genetic Disorders) pipeline landscape.

Becker muscular dystrophy (BMD) is one of type of muscular dystrophy, a group of genetic, degenerative diseases primarily affecting voluntary muscles. Symptoms include pain and sensation, difficulty with running, hopping, and jumping, toe walking, breathing problems, cognitive problems and frequent falls.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Becker Muscular Dystrophy - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Becker Muscular Dystrophy (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Becker Muscular Dystrophy (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Becker Muscular Dystrophy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 3 and 5 respectively.

Becker Muscular Dystrophy (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Becker Muscular Dystrophy (Genetic Disorders).
• The pipeline guide reviews pipeline therapeutics for Becker Muscular Dystrophy (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Becker Muscular Dystrophy (Genetic Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Becker Muscular Dystrophy (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Becker Muscular Dystrophy (Genetic Disorders)

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Becker Muscular Dystrophy (Genetic Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Becker Muscular Dystrophy (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Becker Muscular Dystrophy - Overview
Becker Muscular Dystrophy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Becker Muscular Dystrophy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Becker Muscular Dystrophy - Companies Involved in Therapeutics Development
Armgo Pharma Inc
Catabasis Pharmaceuticals Inc
Edgewise Therapeutics
Epirium Bio Inc
Italfarmaco SpA
Milo Biotechnology LLC
PTC Therapeutics Inc
ReveraGen BioPharma Inc
Sarcomed AB
Stealth BioTherapeutics Corp
Tivorsan Pharmaceuticals Inc
Becker Muscular Dystrophy - Drug Profiles
ARM-210 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ataluren - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dextro epicatechin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
edasalonexent - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EDG-5506 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Becker Muscular Dystrophy - Dormant Projects
Becker Muscular Dystrophy - Discontinued Products
Becker Muscular Dystrophy - Product Development Milestones
Featured News & Press Releases
Aug 12, 2020: Epirium Bio announces commencement of phase 1 clinical trial of EPM-01 in Becker muscular dystrophy
Apr 14, 2020: Epirium Bio receives FDA orphan-drug designation for EB 002 ((+)-Epicatechin) for the treatment of duchenne and becker muscular dystrophy
Feb 10, 2016: Catabasis Pharmaceuticals Will Present CAT-1004, a Potential Disease-Modifying Agent in Development for the Treatment of Duchenne Muscular Dystrophy, at the XIV International Conference on Duchenne and Becker Muscular Dystrophy
Jun 30, 2015: Cardero Therapeutics Presents at 2015 Parent Project Muscular Dystrophy Connect Conference
Mar 31, 2015: Cardero Therapeutics Presents at 2015 Muscular Dystrophy Association Scientific Conference
Sep 30, 2014: Becker Trial completed at UC-Davis on the Cardero Therapeutics lead compound
May 31, 2013: Becker Trial initiated at UC-Davis on the Cardero Therapeutics lead compound
Mar 31, 2013: Completed triglyceride trial with Cardero Therapeutics lead compound
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Becker Muscular Dystrophy, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Becker Muscular Dystrophy - Pipeline by Armgo Pharma Inc, H2 2020
Becker Muscular Dystrophy - Pipeline by Catabasis Pharmaceuticals Inc, H2 2020
Becker Muscular Dystrophy - Pipeline by Edgewise Therapeutics, H2 2020
Becker Muscular Dystrophy - Pipeline by Epirium Bio Inc, H2 2020
Becker Muscular Dystrophy - Pipeline by Italfarmaco SpA, H2 2020
Becker Muscular Dystrophy - Pipeline by Milo Biotechnology LLC, H2 2020
Becker Muscular Dystrophy - Pipeline by PTC Therapeutics Inc, H2 2020
Becker Muscular Dystrophy - Pipeline by ReveraGen BioPharma Inc, H2 2020
Becker Muscular Dystrophy - Pipeline by Sarcomed AB, H2 2020
Becker Muscular Dystrophy - Pipeline by Stealth BioTherapeutics Corp, H2 2020
Becker Muscular Dystrophy - Pipeline by Tivorsan Pharmaceuticals Inc, H2 2020
Becker Muscular Dystrophy - Dormant Projects, H2 2020
Becker Muscular Dystrophy - Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Becker Muscular Dystrophy, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Targets, H2 2020
Number of Products by Stage and Targets, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020

COMPANIES MENTIONED

Armgo Pharma Inc
Catabasis Pharmaceuticals Inc
Edgewise Therapeutics
Epirium Bio Inc
Italfarmaco SpA
Milo Biotechnology LLC
PTC Therapeutics Inc
ReveraGen BioPharma Inc
Sarcomed AB
Stealth BioTherapeutics Corp
Tivorsan Pharmaceuticals Inc